Skip to main content

Table 3 Summary of EGFR-TKI delivered among EGFR mutation positive patients

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

 

EGFR mutation positive

 

Low PCV

High PCV

(< 2.2 ng/ml) (n= 72)

(≥ 2.2 ng/ml) (n= 49)

 

Gefitinib

Erlotinib

Gefitinib

Erlotinib

 

No.

%

No.

%

No.

%

No.

%

First-line

20

28

5

7

23

47

2

4

Second-line

21

29

11

15

14

29

8

16

Third-line

9

12

6

8

3

6

4

8

Further-line

2

3

14

20

2

4

4

8

Unadministered

20

28

36

50

7

14

31

63

  1. PCV: pretreatment CYFRA 21–1 value.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us